Common Isolates among Suspected Cases of Septicemia with a Special Emphasis on Multidrug Resistant Strains

M. Shabnum*, P. Sreenivasulu Reddy and P. Vasundhara

Department of Microbiology, Narayana Medical College, Nellore, Andhra Pradesh – 524003, India

*Corresponding author

Introduction

Bacteremia is the presence of bacteria in the blood. Septicemia is a condition in which bacteria multiply within the blood and their toxic products cause harm to the host producing an infection. It is the leading cause of death with mortality rates ranging from 20% to 50%, especially in Intensive Care Units, prolonging the hospital stay of the patients. Microbial invasion of blood stream can have serious immediate consequences including shock, multiple organ failure, DIC and death (Patricia M. Tille; Stephane Hugonnet et al., 2004).

ICU patients create an environment for infection because of debilitating effect of...
prolonged hospitalization as well as usage of various medical equipments like airways and catheters (Mohanasoundaram, 2011). A critical issue is the time one can declare the blood culture as positive or negative (Vinod Kumar, 2005). Even if the blood cultures are done, the report of isolation and susceptibility is available after 72hours or more with the use of Ampicillin and an aminoglycoside or a 3rd generation cephalosporin being the empirical treatment (Bhattacharjee et al., 2008).

Surveillance to describe varied pathogens causing sepsis and their changing antimicrobial susceptibility pattern is important (Kaistha et al., 2010).

With the production of ESBLs, Carbapenemases in case of Gram Negative Bacteria and MRSA emerging as major threats, this situation raises a serious concern regarding faster microbial recovery using automated BacT/ALERT 3D blood culture system and appropriate antibiotic use.

In the light of the above challenges, present study was aimed to isolate the microbial agents from suspected cases of sepsis along with antibiotic sensitivity pattern with special emphasis on MRSA, ESBL, AmpC and Carbapenemase producing strains.

Aims and objectives

To isolate the common organisms from the blood samples of suspected cases of septicemia from the hospitalized patients in PICU, NICU and Intensive Care Unit

To study the antimicrobial susceptibility pattern of the various bacterial isolated.

To know the prevalence of Multidrug Resistant strains among the various organisms isolated by detecting MRSA, ESBL, AmpC and Carbapenemase production.

Materials and Methods

Ethical clearance

Blood Samples were obtained from patients following approval of the study by the Institutional Ethical Committee.

Study design

It was a prospective study conducted in Department of Microbiology, Narayana Medical College, from July 2014 to June 2015 over a period of 1 year with a sample size of 300

Inclusion criteria: Suspected cases of septicemia and Pyrexia of unknown origin

Exclusion criteria: Patients on antibiotics

Method of blood collection

Two blood samples were collected in from different sites from the suspected cases of sepsis by following the standard aseptic precautions at bed side

Volume of blood from adult: 6-10ml

Volume of blood from neonate: 1 – 2ml

Volume of blood from children: 3 - 5ml

The blood was collected in Blood culture bottles (Adult and Pediatric bottles) and was kept in BacT/ALERT machine for incubation.

Once the growth was there, machine beeped (6-24hrs).

Gram-stain

Smears were made from the positive samples, heat-fixed and stained by Gram-stain and the preliminary report was given to the clinician.
**Culture and identification**

Plating was done on Blood Agar, Nutrient Agar, MacConkey’s Agar, and Chocolate Agar and incubated at 37°C aerobically for 18-24 hours. Growth was identified by standard biochemical reactions (Oxidase test, Catalase Test, Coagulase test, Indole test, Citrate Utilization Test, TSI, Urease Production Test, MR, VP and Hugh Leifson’s Oxidative Fermentative test) Depending on the morphology of colonies, the presumptive identification of the organism was made.

Candida species were identified by Germ Tube Test.

**Antibiotic susceptibility testing**

Antibiotic susceptibility testing was done by the Kirby-Bauer disc diffusion method. The antibiotics used were according to CLSI guidelines using HiMedia discs.

The following drug discs were used for Enterobacteriaceae: Ampicillin (10μg), Cefixime (5μg), Cotrimoxazole (25μg), Ofloxacin (5μg), Amikacin (30μg), Polymyxin B (50 units), Amoxycillin + Clavulanic acid (30μg), Cefoperazone + Sulbactam (75/30μg), Piperacillin + Tazobactam (100/10 μg), Imipenem (10μg), Aztreonam (30μg)

Clindamycin (2μg), Amoxycillin + Clavulanic acid (30μg), Piperacillin + Tazobactam (100/10μg), Linezolid (30μg)

**Drug resistance pattern detection**

**Testing for MRSA**

The test strains resistant to Oxacillin were tested for Methicillin resistance using cefoxitin discs. Lawn culture of the test strain was made onto Mueller-Hinton Agar (MHA) and Cefoxitin disc (30μg) was placed in the centre. The zone of inhibition was measured after overnight incubation at 37°C.

Interpretation: ≤ 21mm = MRSA, ≥ 22mm = MSSA

**Testing for ESBL production**

Lawn culture of the test strain was made onto Mueller Hinton Agar and Ceftazidime and Ceftazidime + Clavulanic acid discs were placed and incubated aerobically overnight at 37°C.

Interpretation: A ≥ 5mm increase in zone diameter for Ceftazidime versus zone diameter for Ceftazidime + Clavulanic acid was considered as ESBL producer.

**Testing for Carbapenemase production**

1:10 dilution of the 0.5 McFarland suspension of E.coli ATCC 25922 was taken and lawn culture was done onto Mueller Hinton Agar. Ertapenem disc was placed; the test organism was streaked in a straight line from the edge of the disc and incubated overnight at 37°C. Interpretation: Enhanced growth at the intersection of the streak and zone of inhibition was considered positive for carbapenemase production. No enhanced growth at the intersection was considered negative for carbapenemase production.
Testing for AmpC production

Lawn culture of the test strain was made onto Mueller Hinton Agar and Cefoxitin and Ceftriaxone discs were placed with a distance of 20mm from each other and incubated aerobically overnight at 37°C.

Interpretation: A flattening or blunting of the zone between the cefoxitin disc and the ceftriaxone disc was considered as AmpC β-lactamase producers.

Results and Discussion

Among 300 clinically suspected cases of septicemia selected for the study, blood culture positivity rate was 24.66%. Studies conducted by Joshi et al., (2000) (25%), Muley et al., (2015) (26.6%), and Iregbu et al., (2006) (22%) showed similar rates on contrary to higher rates of isolation by Parikh Madhubala and Singh Nandon (1995) (47%), Surya Kirani and Sailaja (2015) (42%) and Jaslyn et al., (2013) (42%). The variation in culture positivity can be attributed to the volume of blood collected, type of blood culture medium and automated blood culture systems. Male preponderance was observed (78.37%) similar to observation made by Anitha Sharma et al., (1993) (74%) in their study.

Of the culture positives, Gram negative organisms were the commonest isolates (83.78%), similar to Gram Negative preponderance in Culture positive cases reported by Sharma Anitha et al., (1991) (85%), Mahapatra et al., (2002) (88.45%) in contrast to Gram Positive isolates as most common reported by Kingsley et al., (2013) (62.6%) and Starakis et al., (2010) (58.5%). Low Candida isolation rates (2.43%) were found to be similar to findings by Shashi Gandhi et al., (2013) (2.6%) and Desai et al., (2011) (3.57%). Among the Gram Negative organisms, most common organism isolated was Klebsiella pneumoniae (33.33%) followed by Escherichia coli (16.66%), Citrobacter koseri (16.66%) and Acinetobacter baumannii (16.66%). Studies done by Surya Kirani and Sailaja (2015) and Rahul Kamble and Rajesh Ovhal (2015) reported similar pattern of isolation with Klebsiella pneumoniae (33.5%) being most common followed by Escherichia coli (14.3%), Acinetobacter species (9.5%) and Klebsiella pneumoniae (35.55%) respectively. Coagulase Negative Staphylococcus (CONS) was most common Gram Positive organism isolated (8.1%) similar to findings by Rahul Kamble and Rajesh Ovhal (2015) (16.9%), Jaslyn et al., (2013) (13.92%) and Mahapatra et al., (2002) (2.3%). Leon et al., mentioned that presence of CONS in the blood can no longer be considered as contaminant especially in patients in critical care units where it is associated with significant mortality.

Out of 12 culture positive pediatric patients, 100% had lethargy, 83.33% presented with respiratory distress, tachycardia and chest retractions and 33.33% with hyperthermia, in comparison to reports wherein majority of sepsis cases presented with refusal to feeds (42.7%), fever (41.7%) by Shrestha et al., and lethargy (73.24%) by Rahul Kamble and Rajesh Ovhal (2015). In case of adult patients, hyperthermia, tachycardia and tachypnoea were most common parameters observed (100%) keeping in mind report by Coburn et al., (2012) that fever alone cannot be a criteria to predict bacteremia (Table 1–15 and Fig. 1).

Most common predisposing factors evaluated were found to be respiratory condition (48.38%) followed by renal condition (32.25%), DM (22.58%) similar to study conducted by Starakis et al., (2010) who found lower respiratory tract infection (39.1%) as major risk factor followed by UTI (25.7%).
### Table 1 Distribution of total samples

|                | Number | %  |
|----------------|--------|----|
| Adult          | 222    | 74 |
| Pediatric      | 78 (NICU – 46; PICU – 32) | 26 |
| Total          | 300    | 100|

### Table 2 Number of culture positive samples

|                  | Number | %  |
|------------------|--------|----|
| Culture positives| 74     | 24.66 |
| No growth        | 226    | 75.33 |
| Total            | 300    | 100 |

### Table 3 Gender distribution among culture positive samples

| Gender   | Number | %  |
|----------|--------|----|
| Male     | 58     | 78.37 |
| Female   | 16     | 21.62 |
| Total    | 74     | 100 |

### Table 4 Distribution of culture positive samples

|                | Number | %  |
|----------------|--------|----|
| Adult          | 62     | 83.78 |
| Pediatric      | 12     | 16.21 |
| Total          | 74     | 100 |

### Table 5 Organism wise distribution

| ORGANISM                  | NUMBER (N=74) | %  |
|---------------------------|---------------|----|
| **GRAM NEGATIVE ORGANISMS**|               |    |
| Klebsiella pneumoniae     | 62            | 83.78 |
| Escherichia coli          | 12            | 16.21 |
| Pseudomonas aeruginosa    | 10            | 13.51 |
| Citrobacter koseri        | 8             | 10.81 |
| Acinetobacter baumannii   | 6             | 8.10 |
| Citrobacter freundii      | 2             | 2.70 |
| Klebsiella oxytoca        | 2             | 2.70 |
| **GRAM POSITIVE ORGANISMS**|               |    |
| Coagulase Negative Staphylococci | 4 | 5.40 |
| Staphylococcus aureus     | 2             | 2.70 |
| **FUNGAL**                |               |    |
| Candida albicans          | 6             | 8.10 |
Table 6 Organisms isolated from culture positive adult patients

| ORGANISM                      | NUMBER (N=62) | %    |
|-------------------------------|---------------|------|
| **GNB**                      |               |      |
| *Klebsiella pneumoniae*       | 18            | 29.03|
| *Escherichia coli*            | 10            | 16.12|
| *Pseudomonas aeruginosa*      | 10            | 16.12|
| *Citrobacter koseri*          | 6             | 9.67 |
| *Acinetobacter baumannii*     | 4             | 6.45 |
| *Citrobacter freundii*        | 2             | 3.22 |
| *Klebsiella oxytoca*          | 2             | 3.22 |
| **GPC**                      |               |      |
| Coagulase Negative Staphylococci | 2    | 3.12 |
| *Staphylococcus aureus*       | 2             | 3.12 |
| **FUNGAL**                   |               |      |
| Candida                       | 6             | 9.67 |

Table 7 Organisms isolated from culture positive pediatric patients

| ORGANISM                      | NUMBER (N=12) | %    |
|-------------------------------|---------------|------|
| **GNB**                      |               |      |
| *Klebsiella pneumoniae*       | 4             | 33.33|
| *Escherichia coli*            | 2             | 16.66|
| *Citrobacter koseri*          | 2             | 16.66|
| *Acinetobacter baumannii*     | 2             | 16.66|
| **GPC**                      |               |      |
| Coagulase Negative Staphylococci | 2    | 16.66|

Table 8 Screening criteria in culture positive adult patients

| CRITERIA          | NUMBER (N=62) | %    |
|-------------------|---------------|------|
| Hyperthermia      | 62            | 100  |
| Tachycardia       | 62            | 100  |
| Tachypnoea        | 62            | 100  |
| Leukocytosis      | 60            | 96.77|
| Leukopenia        | 2             | 3.22 |

Table 9 Screening criteria for culture positive pediatric patients

| CRITERIA          | NUMBER (N=12) | %    |
|-------------------|---------------|------|
| Lethargy          | 12            | 100  |
| Respiratory distress | 10      | 83.33|
| Tachycardia       | 10            | 83.33|
| Chest retraction  | 10            | 83.33|
| Poor activity     | 6             | 50   |
| Hyperthermia      | 4             | 33.33|
| Poor feeding      | 2             | 16.66|
### Table 10 Predisposing factors among culture positive adult patients

| PREDISPOSING FACTOR         | NUMBER (N=62) | %    |
|----------------------------|---------------|------|
| Respiratory Condition      | 30            | 48.38% |
| Renal condition            | 20            | 32.25% |
| Diabetes Mellitus          | 14            | 22.58%
| Hypertension               | 12            | 19.35% |
| >65yrs                     | 12            | 19.35% |
| Cardiovascular condition   | 10            | 16.12% |
| Gastrointestinal condition | 8             | 12.90% |
| Surgery                    | 6             | 9.67%  |
| Pancreatitis               | 6             | 9.67%  |
| Trauma                     | 4             | 6.45%  |
| Poisoning & Snake bite     | 4             | 6.45%  |

### Table 11 Predisposing factors among culture positive pediatric patients

| Predisposing factor       | Number (n=12) | %    |
|---------------------------|---------------|------|
| Preterm                   | 6             | 50   |
| Respiratory infections    | 4             | 33.33% |
| CNS infections            | 4             | 33.33% |
| Low birth weight          | 2             | 16.66% |

### Table 12 Antibiogram of Gram positive cocci

| S.No | Antibiotic                        | CONS (n=4) | Staphylococcus aureus (n=2) |
|------|-----------------------------------|------------|-----------------------------|
|      |                                   | S  S% R  R% | S  S% R  R%                |
| 1    | Ampicillin                         | 1 25 3 75 | 0 0 2 100                   |
| 2    | Oxacillin                          | 2 50 2 50 | 1 50 1 50                   |
| 3    | Cefixime                           | 1 25 3 75 | 1 50 1 50                   |
| 4    | Azithromycin                       | 2 50 2 50 | 1 50 1 50                   |
| 5    | Ofloxacin                          | 3 75 1 25 | 1 50 1 50                   |
| 6    | Amikacin                           | 3 75 1 25 | 1 50 1 50                   |
| 7    | Vancomycin                         | 4 100 0 0 | 1 50 1 50                   |
| 8    | Clindamycin                        | 4 100 0 0 | 1 50 1 50                   |
| 9    | Amoxycillin + Clavulanic acid      | 4 100 0 0 | 2 100 0 0                   |
| 10   | Piperacillin + Tazobactam           | 4 100 0 0 | 2 100 0 0                   |
| 11   | Linezolid                          | 4 100 0 0 | 2 100 0 0                   |
### Table 13 Antibiogram of *Pseudomonas aeruginosa*

| S.No | Antibiotic         | Organism (n=10) | S | S% | R | R% |
|------|-------------------|-----------------|---|----|---|----|
| 1    | Ceftazidime       |                 | 10| 100%| 0  | 0  |
| 2    | Cefipime          |                 | 8 | 80% | 2  | 20%|
| 3    | Cotrimoxazole     |                 | 8 | 80% | 2  | 20%|
| 4    | Ciprofloxacin     |                 | 10| 100%| 0  | 0  |
| 5    | Gentamicin        |                 | 8 | 80% | 2  | 20%|
| 6    | Amikacin          |                 | 8 | 80% | 2  | 20%|
| 7    | Polymyxin B       |                 | 2 | 20% | 8  | 80%|
| 8    | Cefoperazone + Sulbactam |         | 2 | 20% | 8  | 80%|
| 9    | Piperacillin + Tazobactam   |         | 10| 100%| 0  | 0  |
| 10   | Meropenem         |                 | 10| 100%| 0  | 0  |
| 11   | Aztreonam         |                 | 2 | 20% | 8  | 80%|

### Table 14 Antibiogram (Resistance pattern) of Gram negative bacteria

| S.No. | Antibiotic                              | Organism                  | Klebsiella (n=24) | E. coli (n=12) | Citrobacter sp (n=10) | A. baumannii (n=6) |
|-------|-----------------------------------------|----------------------------|-------------------|-----------------|-----------------------|---------------------|
| 1     | Ampicillin                              |                            | 20 (83.33)        | 10 (83.33)      | 10 (100)              | 6 (1000)           |
| 2     | Cefixime                                |                            | 22 (91.67)        | 8 (66.67)       | 10 (100)              | 2 (33.33)          |
| 3     | Cotrimoxazole                           |                            | 16 (66.67)        | 8 (66.67)       | 6 (60)                | 4 (66.67)          |
| 4     | Ofloxacin                               |                            | 10 (41.66)        | 6 (50)          | 0 (0)                 | 0 (0)              |
| 5     | Amikacin                                |                            | 6 (25)            | 2 (16.67)       | 2 (20)                | 0 (0)              |
| 6     | Polymyxin B                             |                            | 0 (0)             | 0 (0)           | 0 (0)                 | 0 (0)              |
| 7     | Amoxicillin + Clavulanic Acid           |                            | 14 (58.33)        | 2 (16.67)       | 8 (80)                | 2 (33.33)          |
| 8     | Cefoperazone + sulbactam                |                            | 20 (83.33)        | 10 (83.33)      | 10 (100)              | 6 (1000)           |
| 9     | Piperacillin + Tazobactam               |                            | 6 (25)            | 2 (16.67)       | 8 (80)                | 0 (0)              |
| 10    | Imipenem                                |                            | 3 (12.5)          | 1 (8.33)        | 2 (20)                | 0 (0)              |
| 11    | Aztreonam                               |                            | 18 (75)           | 12 (100)        | 8 (80)                | 4 (66.67)          |

### Table 15 Multidrug resistant strains among culture positive patients

| MDR strain                     | Number | %    |
|--------------------------------|--------|------|
| MDR strain                     | 18     | 24.32|
| MRSA                           | 2      | 2.7  |
| ESBL producer                  | 12     | 16.21|
| AmpC producer                  | 0      | 0    |
| Carbapenemase producer         | 5      | 6.7  |
Fig. 1 A: MRSA detection: Cefoxitin Disc Diffusion Test; B: ESBL detection: Combination Disc Diffusion Test

Yinnon et al., (1996) reported UTI (58%) as major risk factor. In case of pediatric patients, 50% were preterm, 33.33% has underlying respiratory, CNS infections and Low Birth Weight as major risk factors. Studies by Surya Kirani and Sailaja (2015) and (Vinay et al., 2009) also reported LBW (61.6%, 70%) and preterm (51.6%, 68.4%) as major risk factors.

CONS isolated in our study showed highest resistance to Ampicillin and Cefixime (75%), 50% sensitivity to Oxacillin and Azithromycin. *Staphylococcus aureus* showed 100% resistance to Ampicillin and 50% resistance to Oxacillin, Cefixime, Azithromycin, Ofloxacin, and Amikacin. Similar resistance patterns were observed by Vinod Kumar (2005) [Penicillin (67.8%), Cloxacillin (55.6%)] and Kingsley et al., (2013) [Ampicillin (57.1%)]. 100% sensitivity was observed by all Gram Positive organisms to Amoxycillin+ clavulanic acid, Piperacillin + Tazobactam and Linezolid. *Klebsiella* species were found highly resistant to Cefixime (91.67%), Cefoperazone + Sulbactam, Ampicillin (83.33%) with highest sensitivity to Polymyxin B. Carbapenem resistance in Gram Negative Organisms was found to be 9.6% with similar rates reported by Roy et al., (2002) (10%) and Saghir et al., (13%). Rahul Kamble and Rajesh Ovhal (2015) observed highest resistance to Ampicillin (100%) and 3rd Generation Cephalosporins (70%) and 100% sensitivity to Imipenem. In case of *Pseudomonas aeruginosa*, highest resistance was found against Polymyxin B, Cefoperazone + Sulbactam, Aztreonam (80%) with 100% sensitivity to Ceftazidime, Ciprofloxacin, Piperacillin + Tazobactam and Meropenem.

A study by Roy et al., (2002) showed high resistance to Cefotaxime (50%) and low resistance to Ciprofloxacin, Amikacin (10%) in concordance with our study though Shashi Gandhi et al., (2013) reported 33.33% and 16.67% resistance to Ciprofloxacin and meropenem respectively. Such high frequency of resistance observed towards β lactam antibiotics by various organisms might be due to indiscriminate use of them as 1st line drugs.
Out of 74 culture positive isolates, 18 are Multidrug Resistant Strains. 16.21% of the isolates were ESBL producers with highest being *Klebsiella* species followed by *E. coli* and *Citrobacter*. Studies done by Iregbu *et al.*, showed 11.4% ESBL producers similar to our study though higher rates were reported by Saghir *et al.*, (2009) and Rahul Kamble and Rajesh Ovhal (2015) 58% and 82.5% respectively with *Klebsiella* most common ESBL producer. 6.7% isolates were Carbapenemase producers with *Klebsiella* being predominant organism. Similar low rates were reported by Castanheira *et al.*, (2006-07) (2.7%) and Roy *et al.*, (2002) (10%). In contrary, Gupta *et al.*, (2006) reported 22% Carbapenemase producers. Low MRSA rates of 2.5% reported by us was correlated with study conducted by Neelam Kaistha *et al.*, (2010) (11.11%), though higher rates were reported by Raza *et al.*, (75% in CONS and 41.66% in *S. aureus*).

Though the mortality rate of septicemia has gone down from 90% prior to antibiotic era to 24-25% after the antibiotics came into use, the production of ESBLs, Carbapenemases and evolution of MRSA have made therapeutic options limited. Unfortunately ampicillin no longer seems to have significant activity against most of the organism, showing no role in empirical treatment any more. Ciprofloxacin, Amikacin and Imipenem turned out to be better alternatives in case of *Gram Negative Septicemia* producing economical relief to the patients. ICUs being the place where antibiotic usage is highest, patient to patient transmission of resistant organisms might be an important factor for Multi drug resistance emergence.

With such varied isolation rates, it is important to conduct surveillance studies for implementation of control measures thereby limiting the spread of Multidrug Resistant isolates for better patient outcome.

References

Bhattacharjee *et al.*, - ESBL Producers in neonatal septicemia; Indian Journal of Medical Microbiology (2008), 26 (4): 356-60

Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early Dissemination of NDM -1 and OXA – 182 producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006 – 2007 Antimicrob Agents Chemother 2011; 55: 1274 – 1278

Coburn B, Morris A M, Tomlinson G, Detsky A S, Does this adult patient with suspected bacteremia require blood cultures? JAMA 2012; 308: 502-510

Desai, K.J., S.S. Malek, A. Parikh, Neonatal Septicemia: Bacterial Isolates and their Antibiotics Susceptibility Patterns; Gujarat Medical Journal, February 2011; Vol 66 (1): 13-15

Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to Carbapenems in tertiary care hospital in North India. Ind J Med Res 2006; 124: 95 – 98

Iregbu *et al.*, Bacteriological Profile of neonatal septicemia in a tertiary care hospital in Nigeria, African Health Sci 2006

Jaslyn M. Maurer, Janice M. Burns, Mary R. Godfrey, Carl M Urban, Sorana Segal-Maurer, Frequency of Blood Cultures Performed in a Community Hospital; Open Journal of Medical Microbiology, 2013, 3: 130-134

Joshi S.G *et al.*, “Neonatal Gram Negative Bacteremia”; Indian J Pediatric. 2000; 67: 27:32

Kaistha *et al.*, Etiology and Antiobigram of isolates from neonatal Septicemia; Journal of Infect Dev Ctries 2010; 4(1): 055-057

Kingsley, O.C., A.O Ifeanyi, A.E. Edet, O.C Smart, Bacteriological Profile and Antibiotic Susceptibility Pattern of Suspected Septicemic Patients in Uyo, Nigeria, Res.J.Med.Sci, 2013; 7(2): 35-39

Mahapatra, A., Sk. Ghosh, S. Mishra, D. Pattnaik, K. Pattnaik, S K Mohanty, Enterobacter cloacae: A Predominant Pathogen in Neonatal Septicemia, Indian Journal of
Medical Microbiology, 2002; 20(2): 110-112
Mohanasoundaram, K.M. The Antimicrobial resistance patterns in clinical isolates of *Pseudomonas aeruginosa* in a tertiary care hospital; 2008-2010 (A 3Year study). Journal of Clinical and Diagnostic Research 2011; June; 5; 491-494
Muley VA, Ghadage DP, Bhore AV, Bacteriological profile of neonatal septicemia in a tertiary care hospital from Western India; J Global Infect Dis 2015; 7:75-7
Parikh Madhubala and Singh Nandon; “Rapid Diagnosis of neonatal Bacteremia”, Indian Journal of Microbiology 1995; 13:37-40
Patricia M. Tille, Bailey and Scott’s Diagnostic Microbiology; 13th edition; Blood Stream Infections; 860-877
Rahul Kamble, and Rajesh Ovhal. Bacteriological Profile of Neonatal Septicemia; Int.J.Curr.Microbiol.App.Sci (2015) 4(2): 172-182
Roy, I., A. Jain, M. Kumar, S K Agarwal, Bacteriology of Neonatal Septicemia in a tertiary care hospital of Northern India, Indian Journal of Medical Microbiology, 2002; 20(3): 156 – 159
Saghir, S., M. Faiz, M. Saleem, A. Younus, H. Aziz, Characterization and antimicrobial susceptibility of Gram Negative Bacteria isolated from Bloodstream infections if Cancer Patients on Chemotherapy in Pakistan, IJMM 2009; 27 (4): 341 - 347
Sharma Anitha *et al.*, “Diagnostic and Prognostic role of CRP and mESR in Neonatal Septicemia”, Indian Paediatrics, 1993; 30: 347-349
Sharma Anitha *et al.*, “Evaluation of Sepsis Screen for diagnosis of Neonatal Septicemia”, Indian J Paediatr 1991; 60: 559-563
Shashi Gandhi, K.P. Ranjan, Neelima R, Neha. S, Mahendra M, Incidence of Neonatal Sepsis in a Tertiary Care Hospital: A Overview, Int J Med Sci Public Health 2013; 2: 548-552
Starakis, I., E.E. Mazokopakis, D. Siagris, I. Tsantoula, C.A Gogos, Comparison of Community and Hospital Acquired Bacteremia in a Greek University Hospital: One Year Experience; Med Prac Rev, April 2010; Vol 1 (1): pp 1-8
Stephane Hugonnet *et al.*, Nosocomial Blood Stream Infections and clinical Sepsis; Journal of Emerging Infectious Diseases. January 2004; Vol10-No1
Surya Kirani K.R.L, and B.S.G. Sailaja, Microbiological and Epidemiological Study of Neonatal Septicemia, International Journal of Scientific Research, Aug 2015; Vol 4(8): 118-121
Vinay B.S. Herald Seifert; The Clinical Importance of Microbiological findings in the diagnosis and management of Blood Stream Infections; Clin Infect Dis (2009) 48 (4): S238 – S 245
Vinod Kumar, C.S. Incubation period for culture positivity to detect septicemia in neonates; Indian Journal of Medical Microbiology (2005); 23(4): 270-75; Vol23;No 4
Yinnon, A.M., A. Butnaru, D. Raveh, Z. Jerassy, B. Rudensky, *Klebsiella* Bacteremia: A community versus nosocomial infection, Q J Med 1996; 89: 933-941.

How to cite this article:
Shabnum, M., P. Sreenivasulu Reddy and Vasundhara, P. 2018. Common Isolates among Suspected Cases of Septicemia with a Special Emphasis on Multidrug Resistant Strains. *Int.J.Curr.Microbiol.App.Sci.* 7(03): 711-721. doi: https://doi.org/10.20546/ijcmas.2018.703.083